These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37335337)

  • 41. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multi-omics analysis of TLCD1 as a promising biomarker in pan-cancer.
    Wang S; Zhang M; Sun H; Li T; Hao J; Fang M; Dong J; Xu H
    Front Cell Dev Biol; 2023; 11():1305906. PubMed ID: 38559424
    [No Abstract]   [Full Text] [Related]  

  • 43. Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors.
    Zhao H; Xie R; Zhang C; Lu G; Kong H
    Front Genet; 2022; 13():989460. PubMed ID: 36159971
    [No Abstract]   [Full Text] [Related]  

  • 44. EF-Hand Domain-Containing Protein D2 (EFHD2) Correlates with Immune Infiltration and Predicts the Prognosis of Patients: A Pan-Cancer Analysis.
    Wang Y; Song M; Gao B
    Comput Math Methods Med; 2022; 2022():4878378. PubMed ID: 35341013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 46. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluate the diagnostic and prognostic value of NUSAP1 in papillary thyroid carcinoma and identify the relationship with genes, proteins, and immune factors.
    Gao T; Zhao L; Zhang F; Cao C; Fan S; Shi X
    World J Surg Oncol; 2022 Jun; 20(1):207. PubMed ID: 35710427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genome Instability and Long Noncoding RNA Reveal Biomarkers for Immunotherapy and Prognosis and Novel Competing Endogenous RNA Mechanism in Colon Adenocarcinoma.
    Ren Z; Wang Z; Gu D; Ma H; Zhu Y; Cai M; Zhang J
    Front Cell Dev Biol; 2021; 9():740455. PubMed ID: 34746134
    [No Abstract]   [Full Text] [Related]  

  • 49. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of
    Fei L; Lu Z; Xu Y; Hou G
    Front Genet; 2022; 13():920897. PubMed ID: 36035140
    [No Abstract]   [Full Text] [Related]  

  • 50. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic pan-cancer analysis identifies
    Chen P; Yang X; Wang P; He H; Chen Y; Yu L; Fang H; Wang F; Huang Z
    Ann Transl Med; 2023 Jan; 11(2):121. PubMed ID: 36819495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CCL5 might be a prognostic biomarker and associated with immuno-therapeutic efficacy in cancers: A pan-cancer analysis.
    Huang Y; Wu L; Sun Y; Li J; Mao N; Yang Y; Zhao M; Ren S
    Heliyon; 2023 Jul; 9(7):e18215. PubMed ID: 37519664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and validation of
    Li L; Li F; Xu Z; Li L; Hu H; Li Y; Yu S; Wang M; Gao L
    Front Pharmacol; 2023; 14():1213891. PubMed ID: 37680718
    [No Abstract]   [Full Text] [Related]  

  • 54. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
    Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
    Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Prediction, Immune Microenvironment, and Drug Resistance Value of Collagen Type I Alpha 1 Chain: From Gastrointestinal Cancers to Pan-Cancer Analysis.
    Liu Y; Xue J; Zhong M; Wang Z; Li J; Zhu Y
    Front Mol Biosci; 2021; 8():692120. PubMed ID: 34395525
    [No Abstract]   [Full Text] [Related]  

  • 56. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel prognostic mRNA/miRNA signature for esophageal cancer and its immune landscape in cancer progression.
    Zhao Y; Xu L; Wang X; Niu S; Chen H; Li C
    Mol Oncol; 2021 Apr; 15(4):1088-1109. PubMed ID: 33463006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
    Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
    Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the potential biological value of pyruvate dehydrogenase E1 subunit β in human cancer.
    Rong Y; Liu SH; Tang MZ; Wu ZH; Ma GR; Li XF; Cai H
    World J Gastrointest Oncol; 2024 Jan; 16(1):144-181. PubMed ID: 38292838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deciphering the multidimensional impact of
    Yao Z; Han J; Wu J; Li M; Chen R; Jian M; Yang Z; Wang X; Zhang Y; Hu J; Jiang L
    Heliyon; 2024 Sep; 10(18):e37402. PubMed ID: 39309809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.